Understanding immune responses to a shingles vaccine in patients with kidney disease
PERSISTENCE OF IMMUNE RESPONSES TO THE RECOMBINANT ZOSTER VACCINE IN IMMUNE COMPROMISED HOSTS WITH END-STAGE RENAL DISEASE WITH AND WITHOUT KIDNEY TRANSPLANTATION
This study is looking at how well the shingles vaccine works for people with severe kidney disease or those who have had a kidney transplant, to see if extra doses can help boost their protection against infections.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11014039 on NIH RePORTER |
What this research studies
This research investigates how well the recombinant zoster vaccine (RZV) works in individuals with end-stage renal disease (ESRD) and those who have received kidney transplants. It aims to identify the immune responses and metabolic factors that affect the vaccine's effectiveness in these immunocompromised patients. Participants will receive the vaccine and be monitored over time to assess their immune responses compared to healthy adults. The study will help determine if additional doses of the vaccine improve protection against infections.
Who could benefit from this research
Good fit: Ideal candidates include adults with end-stage renal disease or those who have undergone kidney transplantation.
Not a fit: Patients who are healthy and do not have any immunocompromising conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enhance vaccination strategies for immunocompromised patients, improving their protection against severe infections.
How similar studies have performed: Previous research has shown that the recombinant zoster vaccine is effective in healthy adults, but its effectiveness in immunocompromised populations is less understood, making this research both relevant and necessary.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Weinberg, Adriana — University of Colorado Denver
- Study coordinator: Weinberg, Adriana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.